Drug combinatorial screening was used to identify effective combinations for mutant BRAF melanomas, including those resistant to vemurafenib, and mutant RAS melanomas that are resistant to many therapies.

http://cancerdiscovery.aacrjournals.org/content/early/2012/12/07/2159-8290.CD-12-0408.abstract

 

 

Melanoma Research Foundation

Donate Today

Every day the Melanoma Research Foundation works to make the fight against melanoma easier.
Your donation will help us support patients, fund research and advocate for the melanoma community.